CW-2 Xenograft Model Service for Colon Cancer

The CW-2 xenograft model offers a robust preclinical platform for evaluating therapeutic efficacy against colon adenocarcinoma, leveraging a well-characterized human cell line with defined genetic alterations. At Alfa Cytology, we specialize in constructing and validating CW-2 xenograft models to accelerate your oncology drug development pipeline, providing reliable tumor growth data and pharmacodynamic insights tailored to your research objectives.

Overview of CW-2 Xenograft Model for Colon Cancer

The CW-2 cell line was established from a primary colorectal carcinoma specimen obtained from a 55-year-old female patient of Asian ethnicity. It exhibits classic epithelial morphology and demonstrates robust tumorigenic potential, readily forming colonies in soft agar and establishing xenograft tumors in immunodeficient mouse models. Genetically, CW-2 cells harbor key mutations characteristic of colorectal cancer pathogenesis, including alterations in APC, KRAS, and TP53, alongside an ATM missense mutation (A2843V) that results in low ATM protein expression. These molecular features render the CW-2 model particularly relevant for studying DNA damage response pathways and evaluating agents targeting defective ATM signaling.

In preclinical oncology research, the CW-2 xenograft model has been extensively utilized to assess antitumor activity across diverse therapeutic modalities. The model demonstrates predictable tumor growth kinetics and is responsive to standard-of-care chemotherapeutics as well as novel targeted agents, including ATR inhibitors that exploit its ATM-deficient background. Its well-defined genetic profile and aggressive growth characteristics make CW-2 an indispensable tool for investigating tumor microenvironment dynamics, cancer stem cell biology, and mechanisms underlying therapeutic resistance in colon adenocarcinoma.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colon adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through APC, KRAS, and TP53 mutations, and how treatments intersect with DNA damage response pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for ATM-deficient backgrounds.

Figure 1. Gal-9 inhibits the proliferation of colon cancer cell lines. (Morishita, A, et al., 2021)

Cell Line Information: CW-2

The CW-2 cell line is a well-established human colon adenocarcinoma line with comprehensive molecular characterization. Its ATM-deficient background and key mutations in APC, KRAS, and TP53 make it unique among available colon cancer cell lines and essential for preclinical research targeting DNA damage response pathways in colorectal carcinoma.

Our Services

Alfa Cytology delivers comprehensive CW-2 xenograft model services designed to streamline your preclinical colon cancer research. From cell line authentication and inoculation to endpoint analysis and pharmacodynamic profiling, our integrated approach ensures high-quality, reproducible data that supports informed decision-making in therapeutic candidate selection and mechanism-of-action studies.

Workflow of CW-2 Xenograft Model Construction

Alfa Cytology follows a standardized yet flexible workflow for CW-2 xenograft model construction, ensuring consistency across batches while accommodating client-specific study requirements. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Preparation: CW-2 cells are authenticated via STR profiling and confirmed for mycoplasma negativity. Cells are expanded under optimal culture conditions to ensure logarithmic growth phase at the time of harvest.
2. Cell Harvesting and Quality Check: Cells are harvested using enzymatic dissociation, washed, and resuspended in a serum-free medium matrix. Viability is assessed by trypan blue exclusion, with a minimum threshold of 95% viability required for inoculation.
3. Animal Preparation and Ethical Approval: Immunodeficient mice (typically NOD-SCID or nude mice) are acclimatized under pathogen-free conditions. All procedures are conducted in compliance with institutional animal care and use committee (IACUC) guidelines.
4. Tumor Cell Inoculation: CW-2 cells are subcutaneously injected into the flank region at a standardized density. Alternatively, orthotopic implantation into the cecal wall can be performed for studies requiring organ-specific tumor microenvironment.
5. Tumor Monitoring and Randomization: Tumor growth is monitored by caliper measurement twice weekly. Upon reaching a palpable volume (typically 100--150 mm^3), animals are randomized into treatment groups to minimize baseline bias.
6. Treatment Administration and Data Collection: Test compounds are administered according to the predefined dosing schedule. Tumor dimensions, body weight, and clinical observations are recorded systematically throughout the study duration.
7. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology, immunohistochemistry, biomarker profiling, and pharmacodynamic assessments.

Figure 2: Schematic workflow illustrating the derivation and construction of the CW-2 Xenograft Model at Alfa Cytology.

Case Study-CW-2 Xenograft Model Development

Alfa Cytology has successfully developed and validated the CW-2 xenograft model for multiple preclinical oncology programs targeting colon adenocarcinoma. Our internal dataset demonstrates consistent tumor take rates and dose-dependent growth inhibition in response to reference compounds, providing a reliable benchmark for novel therapeutic evaluation. Detailed efficacy data, tumor growth curves, and pharmacodynamic biomarker results are available upon request under appropriate confidentiality agreements.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your CW-2 xenograft model needs provides distinct advantages that enhance the efficiency and translational value of your preclinical research.

• Verified Cell Line Integrity: Rigorous cell line authentication and quality control protocols ensure model fidelity and reproducibility across studies.
• High Take Rates and Consistency: Customizable study designs accommodate diverse therapeutic modalities, including small molecules, biologics, and combination regimens.
• Comprehensive Analytical Support: Comprehensive endpoint analysis capabilities, from standard tumor growth inhibition to advanced biomarker and pharmacodynamic profiling.
• Tailored Study Designs: Experienced scientific team with deep expertise in colon cancer biology and xenograft model optimization.
• Standardized Protocols: Streamlined project timelines and transparent communication to accelerate your drug development decision-making process.
• Dedicated Project Management: Compliance with international ethical standards and regulatory guidelines for preclinical in vivo research.

Contact Us

Ready to advance your colon cancer research with a validated CW-2 xenograft model? Contact us today to discuss your project requirements, receive a customized study proposal, and learn how Alfa Cytology can support your preclinical oncology program from concept to data delivery. Please reach out to us today via our inquiry form or email to learn more about our CW-2 Xenograft Model services.

For research use only. Not intended for any clinical use.